ArticleScientific reports2025
Rational design, synthesis of some quinolinone-Schiff bases/ pyridazino[4,5-c]quinolinones with potent anti-lung cancer and antituberculosis performance.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study reports the synthesis of binary and fused polycyclic hybrids based on quinolinone through the reaction of 3-acetyl-4-hydroxy-1-phenylquinolinone (AHQ) 1 with different amine and hydrazine derivatives to give corresponding Schiff bases 2-6 and hydrazones 8,9a-c. Whereas, formylation of hydrazone 9a, afforded pyrazolylquinolinone carbaldehyde 10. In addition, angular tricyclic systems 14-19 were synthesized from the reaction of hydrazone 8 with different aldehydes involving piperonal, chloroquinoline-3-carbaldehyde, chromene-3-carbaldehyde, ferrocenecarboxaldehyde, glyoxal and terephthalaldehyde. Whereas, the treatment of hydrazone 8 with different ketones afforded the corresponding bis-hydrazones 20-22 instead of the pyridazino skeletons. As well, all the synthesized hybrids were screened for their potential in vitro anti-lung cancer and antituberculosis activities (A549) and H37Rv strains, respectively. The molecular docking studies showed various strong π and hydrogen interactions with the newly synthesized quinolinone scaffolds. Interestingly, compounds 15, 16, and 19 manifested superior activity against both A549 and H37Rv. Interestingly, the most potent compound was 15 with an IC
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.